CEO and Co-Founder, Bexorg
Zvonimir Vrselja, M.D., Ph.D., is cofounder and CEO of Bexorg, a human brain data and AI company developing medicines for neurological disease. He pioneered BrainEx in the Sestan laboratory at Yale University and was first author of the 2019 Nature study introducing the technology.
Vrselja translated that breakthrough into Bexorg. The company uses BrainEx to restore circulation and molecular activity in donated, postmortem human brains, allowing direct measurement of how drugs act in their intended organ.
Under his leadership, Bexorg developed the first ever multi-modal human brain dataset linking single-cell activity with human context, including donor disease and therapeutic context, across hundreds of human brains. Bexorg is developing a world model of human brain biology. This integrated wet-lab/AI loop predicts how drugs act in the human brain, experiments test those predictions directly, and results refine the model.
In collaboration with Biohaven, Bexorg provided human brain pharmacology data and insights to address clinical development risks for Biohaven’s PKM2 activator for neurodegenerative and neuroinflammatory disorders. The drug is now in phase 1, marking a milestone for drug development informed by direct experiments in donated human brains. Vrselja assembled the drug discovery team using the platform to build Bexorg’s wholly owned drug portfolio.
Vrselja earned his M.D. and Ph.D. from J. J. Strossmayer University, where he trained in clinical radiology and neuroanatomy, followed by postdoctoral training at Yale University. He has published multiple Nature papers and is a Schmidt Futures Innovation Fellow and finalist for the Eppendorf & Science Prize for Neurobiology.
Follow him on LinkedIn.